Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-497"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-497"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-4982
lpv:speaker	lp:Frédérique Ries2
lpv:spokenAs	member; ENVI (2009-07-16--2012-01-18)3 member; Delegation for relations with Israel (2009-09-16--2014-06-30)3 member; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3 member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2009-09-16--2014-06-30)3 unknown; Mouvement Réformateur (2009-07-14--2014-06-30)3 member; FEMM (2009-07-16--2012-01-18)3 substitute; ITRE (2009-07-16--2012-01-18)3 member; Delegation to the EU-Chile Joint Parliamentary Committee (2009-09-16--2014-06-30)3 member; ALDE (2009-07-14--2014-06-30)3
lpv:translated text	"Mr President, pharmacovigilance should be to medicinal products what haemovigilance is to blood and organ vigilance is to organs: a comprehensive insurance policy. Having said which, I should, in fact, say a quasi-comprehensive insurance policy, because we know – as has been said – that taking medicinal products, even strictly in keeping with the package leaflet, is not without adverse reactions. Sometimes, it is even fatal; 197 000 deaths a year, as our rapporteur, Mrs McAvan, pointed out in her explanatory statement, just as she also pointed out this afternoon the tragic episodes which have marked the history of this sector. This statistic is unacceptable. It needs to be significantly reduced through more efficient collaboration between all links in the chain. That is why I support all the proposals made in this direction: better coordination through the EudraVigilance database, improved patient information and, as has been said, better information in both senses – Mrs Rivasi and Mr Turmes explained this – as well as real transparency in the work of the new European Pharmacovigilance Risk Committee. To conclude, independent expertise – and I shall come back to this time and again – is the alpha and omega of all our policies. It is vital here in order to strengthen patients’ confidence."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph